Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.
Age ≥ 40 years old;
Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))[1];
Have no history of drug adjustment within 4 weeks before treatment and the entire study period;
The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;
Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above);
Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.